touchRESPIRATORY coverage of CHEST 2025:

The CHEST 2025 annual meeting brought together pulmonary, critical care, and sleep medicine experts to share emerging science, clinical insights, and forward-looking innovations shaping respiratory care. Through focused conversations with leaders across the field, these interviews highlight practical, practice-ready insights that clinicians can bring directly to patient care.

View our highlights from this event below.   

Advancing smoking cessation in respiratory care: Evidence, equity, and clinical practice

Smoking cessation is essential in chronic respiratory disease, yet clinicians must navigate evolving evidence, diverse patient needs, and persistent inequities in care. In this Q&A, Dr Humayun Anjum discusses current data on e-cigarettes, practical strategies for individualising cessation support, and approaches to embedding health equity into clinical practice. He highlights policy, community, and clinical interventions that expand access to evidence-based resources, particularly for underserved populations.

Read our interview with Dr Humayun Anjum (Baylor Scott & White Health, Dallas, TX, USA) here.

Inside CHEST 2025: Pulmonary hypertension diagnosis, therapy, and transplant updates

CHEST 2025 delivered a dynamic, multidisciplinary program showcasing advances in pulmonary, critical-care, and thoracic medicine. Dr Jean Elwing highlights the most impactful PH-focused sessions, including immersive hemodynamic and imaging training, discussions on integrating sotatercept into PAH care, efforts to address disparities in PH care, and key updates at the intersection of transplant medicine and pulmonary hypertension.

Read our interview with Dr Jean Elwing (UC Medical Center, Cincinnati, OH, USA) here.

Clinical trials in fibrotic ILDs: New therapeutic targets and the rise of precision medicine

As the therapeutic landscape for fibrotic interstitial lung diseases (ILDs) continues to evolve, new trials are redefining targeted treatment and precision medicine approaches. In this Q&A, Dr Tejaswini Kulkarni discusses her CHEST 2025 presentation, highlighting emerging therapeutic targets, the role of biomarkers, recruitment challenges, and innovative trial designs shaping the future of fibrotic ILD research.

Read our interview with Dr Tejaswini Kulkarni (The University of Alabama at Birmingham, Birmingham, AL, USA) here.

Managing PAP nonadherence in obstructive sleep apnoea: Key strategies and insights

Positive airway pressure (PAP) therapy is the standard treatment for obstructive sleep aponea (OSA), but many patients struggle with adherence due to discomfort or intolerance. This interview with Dr Carolyn D’Ambrosio explores the key factors driving PAP nonadherence, practical strategies to improve compliance, promising alternative therapies, and emerging innovations aimed at personalizing treatment for challenging cases.

Read our interview with Dr Carolyn D’Ambrosio (University of Miami Miller School of Medicine, Miami, FL, USA) here.

Allergic rhinitis in 2025: Expert strategies for optimizing treatment and clinical best practice

Allergic rhinitis is a common and often underdiagnosed condition that can impact asthma control, sleep, and daily functioning. In this Q&A, Dr Syed Shahzad Mustafa discusses his CHEST 2025 presentation, reviewing first-line therapies, allergen avoidance strategies, and the evolving role of immunotherapy and biologics, offering practical guidance for clinicians to optimize patient care in 2025.

Read our interview with Dr S Shahzad Mustafa (Rochester Regional Health, Rochester, NY, USA) here.